Product of the week

Laser Option for New Gallios Flow Cytometers
Vergrößern

Beckman Coulter Life Sciences

Laser Option for New Gallios Flow Cytometers

A 561 nm laser option, available for new 561 nm-laser ready Gallios* flow cytometers from Beckman Coulter Life Sciences, will be on view at CYTO 2012, June 23-27 in booth 319 at the Congress Center in Leipzig, Germany. The 561 nm laser option provides researchers with the ability to analyze a greater range of fluorescent proteins and to more efficiently excite PE/PE tandems. Optimal excitation is offered for red fluorescent proteins such as mCherry and DsRed, which are being increasingly used in research labs.

Yellow-green excitation provided at 561 nm produces less autofluorescence in cells, increasing the signal-to-noise ratio for PE and DsRed detection.  Since 561 nm excitation is well separated from fluorescein and GFP emission, there is virtually no crossover contamination in the green detection channel, allowing simultaneous fluorescein, or GFP detection, without blocking optics.

The new laser is externally coupled through an optical fiber and can be field installed on new Gallios 561 nm-laser ready analyzers.  The 561 nm laser will be passed to the flow cell collinearly with the 488 nm laser during acquisition.

Available configurations for the Beckman Coulter Life Sciences’ Gallios flow cytometers are: 6 colour/2 laser, 8 colour/2 laser, 10 colour/3 laser and 10 colour/4 laser – the last configuration reflecting the 561 nm option. Six fluorescence detectors provide simultaneous acquisition of up to six fluorescence signals. Concurrent measurements of integral, peak and width are available for all parameters, including scatter and fluorescence signals.

“Expanding the colour options on the Gallios cytometer will extend the applications of the instrument for research scientists,” said Mario Koksch, director of project management and strategy at Beckman Coulter Life Sciences.  “Researchers will be able to further refine their studies using the full capabilities of the cytometer.”

Gallios cytometers feature an innovative forward-scatter detector that provides up to three measurements of cell size and visualization of particles down to 0.404 mm in diameter.  A side-scatter detector incorporates an independently focused, high-performance photodiode with electronic attenuation. A selection of up to 62 parameters can be processed per analysis, at acquisition rates of 25,000 events-per-second, with high yield.  Easily interchanged optical filters facilitate detection of a variety of dyes and wavelengths.


For more information: 

Beckman Coulter Life Sciences

Hillary Hunter, Public Relations

Tel: +1 714 961 5620

hillaryhunter@beckman.com

www.beckmancoulter.com

GE Healthcare

Designed for efficient, small-scale purification and screening of histidine-tagged proteins from different sources.

GE Healthcare

His Mag Sepharose Ni products are magnetic beads designed for efficient, small-scale purification/screening of histidine-tagged proteins from different sources. Histidine-tagged proteins are captured using immobilized nickel ions followed by collection of the beads using a magnetic device. You can use magnetic beads to simplify sample handling during small-scale purification.

His Mag Sepharose Ni delivers:

  • High-capacity small-scale purification of histidine-tagged proteins from different sources
  • High purity and yield
  • Easy parallel screening of histidine-tagged proteins with high repeatability
  • Scalability—Simple capture of histidine-tagged proteins from small or large sample volumes (low microliter to milliliter scale)


The beads are available in three pack sizes: 2 × 1 ml 5% medium slurry, 5 × 1 ml 5% medium slurry, and 10 × 1 ml 5% medium slurry—a 1 ml 5% medium slurry is the same as 50 μl sedimented medium. A 1 ml medium slurry is sufficient for 5 purification runs according to the recommended protocol.

Together with MagRack 6, a separation tool for handling the beads in microcentrifuge tubes, up to six samples can be processed in parallel. You can easily screen a larger number of samples in parallel with high throughput on a robotic device.


Simplified handling:

The magnetic bead format has excellent properties for small-scale experiments. The high density of the beads allows rapid capture by magnetic devices while the visibility of the beads ensures reliable collection of the bound histidine-tagged proteins in the purification procedure. The characteristics of the media are summarized in Table 1. All the products are provided with protocols optimized for purification of histidine-tagged proteins.


Tabel 1. Characteristics of His Mag Sepharose Ni

  • Matrix: Highly crosslinked spherical agarose (Sepharose) including magnetite
  • Metal icon capacity: 21µmol Ni2+/ml medium
  • Binding capacity: approx. 50mg histidine-tagged protein/ml medium (approx. 500µg/purification run)
  • Particle size: 37 to 100µm
  • Working temperature: Room temperature and + 4ºC
  • Storage solution: 20% ethanol, 5% medium slurry
  • Storage temperature: Room temperature

     

Contact:

GE Healthcare Europe GmbH

Dr. Michael Walther
EMEA Marketing Manager Electrophoresis

T    + 49 2293 816 749
M   + 49 173 574 9413
F    + 49 5564 204 593

Michael.Walther@ge.com

www.gelifesciences.com

BIOTECON

To fulfill its responsibility towards the consumer, BIOTECON Diagnostics decided to develop high-quality detection kits for food allergens.

BIOTECON Diagnostics

To fulfill its responsibility towards the consumer, BIOTECON Diagnostics decided to develop high-quality detection kits for food allergens. Therewith, the well-known and respected spectrum offoodproof® real-time PCR kits is extended by another interesting product division.

The first allergen kits that will be launched by the company from Potsdam, Germany, are the foodproof® Celery Detection Kit and the foodproof® Gluten Detection Kit. More allergen kits for the detection of soy, peanut and hazelnut will follow soon. In combination with the foodproof® Sample Preparation Kit III for theextraction of plant DNA, this kits allows simple and safe detection of allergens in all kind of foods. Depending on the source of literature the prevalence of food allergies is between 2 – 4 % for adults and 4 -8% for children.

The foodproof® Sample Preparation Kit III allows the extraction of highly purified DNA even from complex foods or processed matrices. To validate the foodproof® Allergen Detection Kits final products, raw materials and swab samples have been successfully tested. The kit cannot be only used for foods, finished products and raw materials, but also for cleaning validations. In addition, BIOTECON Diagnostics has developed a standardized reference material, Allergen RM 800, to create a standard curve for exact quantification.

More allergen kits for the detection of mustard, sesame, lupine and crustacean will be developed next year. Also it is planned to develop multiplex kits, to detect up to three different allergen-parameters within one reaction.

Food allergens became more important, because the frequency in the population has grown in the last decades. The reasons are still not totally clear; often it is credited to changing environmental influences and diets. Even the smallest amounts of allergens can cause severe allergic reactions up to life-threatening symptoms. For the consumer, the only protection is avoidance. According to EU-regulation 2007/68/EG 14, different allergenic ingredients have to be labeled in Europe on the products. Until now there is no threshold value in Europe or elsewhere. Therefore, the zero tolerance rule applies, even foods that only contain traces of allergens have to be labeled accordingly.

Dr. Kornelia Berghof-Jäger, Chief Executive Officer (CEO) of the Germany-based corporation BIOTECON Diagnostics therefore announced that „the expansion of our product portfolio by test kits for the detection of food allergens is a consequent continuation of our strategy to cover all aspects of food safety diagnostics bymolecular methods.“

„The new product line allows the users of our foodproof® system to enter new markets with the existing laboratory equipment without any additional financial investments.”  emphasizes Alois Schneiderbauer, Chief Business Officer (CBO) of BIOTECON Diagnostics stated.

Further information can be found on www.bc-diagnostics.com.


Contact:

Public Relations: Product Information:

Alois Schneiderbauer, CBO Benjamin Junge, Senior Product Manager

phone: +49 (0) 331 2300-200 phone: +49 (0) 331 2300-244

fax: +49 (0) 331 2300-299 fax: +49 (0) 331 2300-299

aschneiderbauer@bc-diagnostics.com bjunge@bc-diagnostics.com


BIOTECON Diagnostics

Hermannswerder 17

14473 Potsdam – Germany

phone: +49 (0) 331 2300-200

fax: +49 (0) 331 2300-299

email: bcd@bc-diagnostics.com

web: www.bc-diagnostics.com

METTLER TOLEDO

METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications.

METTLER TOLEDO

The new PBK9 and PFK9 Weighing Platforms provide the rugged and reliable operation customers have come to expect from METTLER TOLEDO, paired with advanced technology for high-precision weighing.

Benefits of PBK9 and PFK9 Weighing Platforms include:

  • Outstanding accuracy: The platforms are ideally suited for all weighing processes in which quality is critical and tolerances need to be minimized.
  • Reliable performance: The platforms notify the operator when recalibration or adjustments are necessary due to environmental changes.
  • Easy maintenance: Automated calibration with a built-in calibration weight and plug-in cables allow for easy maintenance.
  • Versatile and Robust: The robust load cell with integrated overload protection and IP66/IP68 ingress protection makes the platforms suitable for a variety of challenging environments including wet areas, locations with heavy dust or workplaces that need regular cleaning.

The PBK9 and PFK9 Weighing Platforms virtually eliminate the impact of environmental interferences that cause errors and result in wasted ingredients or rejected batches. Advanced Monobloc and filter technology guarantees the highest precision and reliability possible.

In addition, the PBK9 and PFK9 weighing platforms are excellent standalone solutions and they also operate well as components in applications ranging from counting and formulating to filling. PBK9 and PFK9 Weighing Platforms offer multiple options, including mild, galvanized or stainless-steel for applications in wet, dusty, harsh or hazardous environments. Nine sizes and twelve capacities from 0.6 kilograms to 3 tons with resolutions up to 750,000 divisions respectively 30,000e (legal for trade) are available. All platforms can be connected to numerous METTLER TOLEDO terminals or directly connected to a control system.

For more detail visit: www.mt.com/PBK9


Media Contact:

Melissa Braithwaite

METTLER TOLEDO

Melissa.Braithwaite@mt.com

614-841-7348

Brady

From basic label design and printing to advanced import and editing options, LabelMark software improves the label-making experience for the electrical, industrial, aerospace, laboratory and telecom industries.

BRADY

New LabelMark™ 6 software takes the hassle out of designing and printing labels. With an improved user interface and app-based navigation combined with Brady’s proven interactive label creation and single-click importing and serialization, you have high performance label printing that has never been easier.

Label Printing with an improved user interface:

  • Easy-to-use apps for creating wire harness, control panel and laboratory labels
  • Insert and edit AutoCAD layers, area of interests or entire files
  • Automatically repeat text on multiple lines of a label with LabelMark wire marker tool
  • Multi-label view for true representation of label formats
  • Adjust each individual label’s length in your print file

Data Management:

  • Quickly import data onto a label from an external data source
  • One-step serialization of data
  • “Check error” function to locate any import errors in prior to printing

Label Printing:

  • Assign label materials to a specific printer for dedicated printing
  • Manage multiple files in a single job by grouping wire markers, push buttons, rating plates, and terminal block labels into one job file
  • Bi-directional communication with the IP, BMP®41, BMP®51,BMP®53, BMP®71 and BBP®33 printer series for automatic label format loading

For more information, visit BradyID.com/labelmark

ProteinSimple

Gel-free. Blot-free. Hands-free. A Simple Western is the Western you know well, only simplified.

ProteinSimple

Gel-free. Blot-free. Hands-free.

A Simple Western is the Western you know well, only simplified. It is not a workaround to the existing process, a Western-like substitute, or a partial solution. It's the real thing, completely reinvented. We at ProteinSimple think that's something to get excited about!

Get your time back. Load your samples in Simon, Sally or Peggy, press start and go enjoy your new hands-free time. Come back a few hours later to fully analyzed results.
Get more consistency. People introduce variability—we arehuman after all. Simple Westerns are fully automated, so they just give you more reproducible data.
Get truly quantitative. Since blot transfer of proteins isn't needed, you can get straight to real, quantitative results.
Get more efficient. Sometimes you can only squeeze out enough sample for one experiment. Simple Westerns require a lot less protein and antibody so you have enough for those replicates.


• Learn about Simple Westerns
• Learn about Peggy
• Learn about Sally
• Learn about Simon
• Learn about NanoPro 1000
• Learn about Compass Software 21 CFR Part 11 Compliance
• Simple Western Systems Comparison Chart


Contact:

Dr. Markus Goddemeier

Sales Specialist

T: +49 (0)761 477 07 63

M: +49 (0)162 985 79 53

www.proteinsimple.com

Novozymes Biopharma

A novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharma’s recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.

Novozymes Biopharma

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

Designed by R-Tech Ueno, RU-101 ophthalmic solution is being trialled as a therapy for severe dry eye, for which no effective treatment is currently available. The recombinant human albumin is part of Novozymes Biopharma’s albumin range. Novozymes Biopharma has a strong reputation in the industry for helping customers in the safe and successful commercialization and approval of new products.

The prevalence of severe dry eye, where patients suffer from instability of the tear film, continues to increase. It is the most diagnosed of all ophthalmic disorders and estimates put the market at approximately 1.5 billion USD. The trials for RU-101 ophthalmic solution will move ahead in two stages, the first of which will assess safety using a placebo control, and allow confirmation of the maximum dose. The second stage will then use this maximum dose for 12 weeks to evaluate the safety and effectiveness of RU-101 ophthalmic solution.

Dermot Pearson, Marketing Director at Novozymes Biopharma said, “Novozymes is dedicated to supporting our customers in the drug development and testing stages, and in assisting with the optimisation of their pathways through regulatory approval procedures. We are therefore delighted that RU-101 ophthalmic solution has been approved for clinical testing.”

Novozymes Biopharma’s recombinant albumin is designed to provide quality performance benefits when included in drugs developed by our customers. It was selected as a key component of this novel therapy back in 2011, due to its proven high quality and enhanced safety profile. Animal-free, with an exceptional purity profile and convenient liquid format at room temperature, recombinant albumin delivers consistent levels of quality, leading to reduced lot testing and vendor auditing.

All Novozymes’ recombinant human albumins deliver stable, safe and regulatory compliant ingredients for drug delivery and formulation, and are compliant with the National Formulary (NF) rAlbumin human monograph published by the United States Pharmacopeia (USP). 

For more information on Novozymes Biopharma’s recombinant human albumin range, please visit http://bit.ly/novozymesbiopharma


Contact:                                                          

Novozymes Biopharma:         

Sally Vernon, Marketing Communications Manager

Email: SYKE@novozymes.com

Tel. +44 115 955 3355

TAP Biosystems

TAP Biosystems installs CellBase CT system at PrimeCell to provide multiple Autologous Cell Therapies.

TAP Biosystems

TAP Biosystems, a leading supplier of innovative cell culture systems and consumables for life science applications, is pleased to announce it is installing a system to automate the ex-vivo expansion of autologous cell therapies (CellBase CT™) at Czech-based firm PrimeCell, one of Central and Eastern Europe’s largest regenerative medicine companies.

The CellBase CT system at PrimeCell will be used in their new GMP facility at the National Tissue Centre Inc to rapidly scale up their manual cell culture processes in T-flasks and will provide a fully-contained aseptic cell expansion area. This will allow scientists to manufacture multiple autologous cell therapies from many individual patients in parallel and will enable the company to supply clients, including regional transplant centres in the Czech Republic, with a range of clean autologous therapies.

Dr Ralph von Strandmann, TAP Biosystems' European Sales Manager stated: “With EU funding for new technologies, there has been an increasing interest in manufacturing biotechnology products in Central and Eastern Europe. This has led progressive companies here to realise that utilising efficient methods of manufacturing cell therapies will provide them with a significant advantage in this competitive sector.”

Dr. von Strandmann added: “We are pleased that PrimeCell will be using CellBase CT to automate expansion of their autologous stem cell therapies.  It is an excellent, cost-efficient alternative to labour intensive manual cell culture and could help make autologous cell therapies less expensive and more widely accessible to patients in Central and Eastern Europe.”

Contact:

TAP Biosystems

Matthew Walker

Head of Communications

York Way, Royston

Hertfordshire, SG8 5WY, UK

Tel: +44 (0) 1763 227200

Fax: +44 (0) 1763-227201

matthew.walker@tapbiosystems.com

www.tapbiosystems.com

Molecular Devices

Molecular Devices®, market leader in microplate reader technology for over 25 years, has announced the launch of its SpectraMax® i3 Multi-Mode Detection Platform with SpectraMax® MiniMax® Imaging Cytometer.

Molecular Devices

The system is available as a stand-alone reader with the option for users to upgrade to additional applications and detection modes such as cellular imaging with the SpectraMax® MiniMax™ Imaging Cytometer, and cartridges for Time-Resolved Fluorescence, Fluorescence Polarization, and AlphaScreen® assays. The highly sensitive instrument accommodates the budget and throughput needs of both small and large laboratories alike.

The SpectraMax i3 Platform's base system features an integrated optical system enabling top and bottom reads for 6 - 384 well microplates and launches with three broad detection modes: luminescence, absorbance, and fluorescence. Patented user-exchangeable cartridge design expands the system's detection capability making it highly versatile, and able to offer application options far exceeding those of standard readers. The MiniMax Imaging Cytometer module adds first of its kind cellular imaging to a multi-mode detection platform, enabling fluorescence and bright field cellular imaging. Combining cellular imaging with microplate-based applications offers new ways for scientists to compress their workflows and increase efficiency. 

Using a combination of a flash lamp for spectral flexibility and light emitting diodes (LEDs) for excitation power, Molecular Devices has developed the patent-pending Spectral FusionTM Illumination to deliver wavelength flexibility whilst maximizing signal strength, ultimately increasing overall performance.

Data from the SpectraMax i3 System is captured and analysed using Molecular Devices' proprietary, industry-leading SoftMax® Pro Software. The newly updated interface and Spectral Optimization Wizard simplifies the workflow and provides powerful data analysis features, eliminating the need for training on additional software. The SpectraMax i3 System is also available for use in GMP and GLP labs when used with the SoftMax® Pro 6.3 GxP Microplate Data Compliance Software.

Klaus Lun, Vice President of Product Marketing at Molecular Devices commented: "This new platform builds on Molecular Devices' experience in life science detection instrumentation development and our commitment to bring additional utility to the microplate reader, further compressing the workflows for our customers. With the MiniMax Imaging Cytometer for cellular imaging, Molecular Devices introduces a new world of cell-based assay application possibilities to the microplate reader.  We will continue to expand the platform's functionality by adding new capabilities to the microplate reader through the introduction of application-specific detection cartridges in 2013."

Please visit our Homepage for more details

Contacts:

Molecular Devices

Carlene Whitehead

Tel: +44 (0) 118 944 4651

Email: Carlene.Whitehead@moldev.com

For more information about the complete product portfolio, visit: www.moleculardevices.com

Advanced Analytical

The Oligo PRO™ 96XT system provides fast, automated and economical size-based purity analysis of single stranded DNA and RNA oligonucleotides, and double stranded RNA interference (RNAi) products.

Advanced Analytical

This dedicated analyzer is capable of analyzing 96 different samples simultaneously by parallel capillary gel electrophoresis with on-line, fixed wavelength UV absorbance detection. Preloaded and optimized separation and capillary conditioning methods simplify and streamline operation. The system can perform unattended analysis of up to 288 samples at once. Application-specific data analysis software provides automated or manual peak integration. The Oligo PRO™ is a proven technology used every day worldwide in production and research labs.


Key Features of the Oligo PRO™ System Include:

  • Low cost per sample.Unsurpassed throughput for oligo purity analysis!
  • Size-based, single nucleotide resolution from 10-mer to 80-mer lengths.
  • Easy to use and maintain with a low cost of ownership.
  • Minimal sample preparation and consumption.
  • DNA oligonucleotide and RNA oligonucleotide analysis.
  • New, native gel analysis for measuring purity and annealing efficiency of dsRNAi products.
  • A full line of available reagents for "turn-key" operation.


For further information please click here.

A Thermo Fisher Scientific Brand

The GeneArt® CRISPR Nuclease mRNA is wild type Cas9 as mRNA, for genome editing using CRISPR-Cas9 technology.

Life Technologies

High-efficiency CRISPR genome-editing tools for multiplex editing

The GeneArt® CRISPR Nuclease mRNA is wild type Cas9 as mRNA, for genome editing using CRISPR-Cas9 technology. Ready-to-transfect Cas9 mRNA circumvents the need for time-consuming cloning steps required when using CRISPR vector systems. Cas9 mRNA can be co-transfected with in vitro transcribed guide RNA (IVT gRNA) or a synthetic gRNA expression cassette containing U6 promoter. The gRNA expressing cassette and IVT gRNA template can be ordered as GeneArt® CRISPR Strings™ DNA, a 500 bp DNA fragment. Following transfection, the Cas9 protein is directed by gRNA to target specific genomic locus. This system allows multiplex genome editing, where multiple target gene sequences can be edited simultaneously in a single transfection reaction with the addition of multiple gRNAs. The system is versatile and simple to use, and changing target specificity only requires a change in the design of the GeneArt® CRISPR Strings™ DNA.

For further information please click here.

Vorherige Seite1/11Nächste Seite

Events

All Events

Whitepaper

Product of the week

Products

Stock list

All quotes

TOP

  • SERODUS (N)2.60 NOK4.00%
  • SUMMIT (UK)4.03 GBP3.87%
  • FLAMEL TECHNOLOGIES (F)23.88 USD3.83%

FLOP

  • BASILEA (CH)103.50 CHF-13.10%
  • ZELTIA (E)3.69 EUR-8.44%
  • DIAMYD MEDICAL -B- (S)9.20 SEK-6.60%

TOP

  • IXICO (UK)34.00 GBP44.7%
  • DBV TECHNOLOGIES (F)78.26 EUR40.4%
  • ZEALAND PHARMA (DK)149.00 DKK31.9%

FLOP

  • BIOTEST (D)25.40 EUR-64.2%
  • BIOTECH PHARMACON (N)9.74 NOK-43.0%
  • TRANSGENE (F)2.81 EUR-25.1%

TOP

  • ADOCIA (F)88.47 EUR590.6%
  • FORMYCON (D)28.89 EUR330.6%
  • DBV TECHNOLOGIES (F)78.26 EUR312.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-70.8%
  • NEOVACS (F)1.02 EUR-68.6%

No liability assumed, Date: 31.07.2015

Current issue

All issues